CCR2 and metabolic dysfunction-associated steatotic liver disease: Similarly, blocking bone marrow-derived macrophage recruitment to the liver by pharmacological or genetic ablation of different chemokine or cytokine pathways improves NAFLD characteristics (e.g. CCR2-CCL24,8–10, CCR2/511,12, CXCR3-CXCL1013,14, CXCL1615, IL-616, TNFα17).